91̽»¨

Advanced therapy medicinal products (ATMPs) are biological medicines based on cells, tissues, and genes. ATMPs enable new ways to treat diseases. However, they are costly treatments that challenge reimbursement models in healthcare.

Pia Johansson, Senior Lecturer in Health Economics at the research group Health Economics, Policy and Evaluation (HEPER) at the Sahlgrenska Academy and researcher at the Centre for Health Governance, has developed a PhD course at the University 91̽»¨ titled Patient access and health economics of ATMPs. The aim of the course is to give students a basic understanding of health economic considerations of ATMPs.

"The focus is on methods for economic evaluation and health technology assessment (HTA) and patient access requirements in Sweden. With the acquired knowledge and skills, the students will be able to describe and discuss reimbursement processes and patient access considerations for ATMPs, and to contribute to the planning and implementation of economic evaluations and HTAs for ATMPs", says Pia Johansson.

The course includes lectures, guest lectures, a guest lecturer panel discussion, group and individual work, and seminars, both campus- and distance-based.